



November 12, 2024

How the "Tax Cuts and Jobs Act" (TCJA, P.L. 115-97) Changed Cost Recovery and the Tax Credit for Research

Tax benefits for investments in research and development are of long-standing interest to Congress and the business community. The 2017 tax cut, commonly referred to as the Tax Cuts and Jobs Act (P.L. 115-97; TCJA), changed the deductibility of research and experimentation (R&E) expenditures by moving from expensing (costs deducted immediately) to five-year amortization (costs deducted ratably over five years). This change took effect in 2022. The TCJA also changed how the deduction of research costs interacts with the research and experimentation (R&E) tax credit. This In Focus provides an overview of the changes to the tax benefits for research stemming from the TCJA.

R&E Credit and Basis Adjustment Basics

Firms may claim one of two R&E tax credits: the 20% "regular" credit, or the 14% "alternative" credit. The regular credit is equal to 20% of qualified research expenses in excess of a base amount that can be no less than 50% of current-year research expenses. CRS estimates that 98% of claims for the 20% credit are subject to the minimum base using Internal Revenue Service (IRS) data, which implies that the credit is effectively 10% (a 20% credit applied to half of qualified expenditures).

The 14% credit applies to research expenditures in excess of half of the average amount of expenditures over the past three years. With growth, somewhat more than half of current-year expenditures would be eligible for the credit. For example, if the annual growth rate of research expenditures is 5%, the base would be 45% of expenditures and the credit would be 7.6% (0.55 times 14%) of current expenditures.

Based on IRS data, CRS estimates that the weighted average effective R&E credit rate—that is, combining both the 20% and 14% credits—is 8.2%.

The prior expensing deduction was reduced by the R&E credit claimed. This reduction is sometimes referred to as a "basis adjustment." Alternatively, firms could claim a full deduction in exchange for reducing the R&E credit by the corporate tax rate, which was equivalent to the basis reduction for corporate taxpayers (but not noncorporate taxpayers).

Requiring a basis adjustment prevents taxpayers from claiming a tax benefit on the same expenditures twice. For example, if a firm has \$100 in qualified expenses and \$8 in R&E credits, the basis adjustment would reduce their deduction for qualified expenses from \$100 to \$92. Alternatively, the taxpayer could claim the full deduction and reduce their credit by the corporate tax rate, producing

the same effect under expensing. Under amortization, however, reducing the deduction would be more favorable because it is smaller than the reduced credit.

The TCJA adjusted the statutory language in Section 280C(c)(1) of the Internal Revenue Code in a manner that appears to have eliminated the basis adjustment. As a result, the change in the TCJA that moved from the most generous form of cost recovery, expensing, to a less generous form of cost recovery, five-year amortization, appears to be partially offset by not having to make a basis adjustment.

Did the TCJA Eliminate the Basis Adjustment?

When the TCJA changed the cost recovery method for R&E expenditures from expensing to five-year amortization, it also changed the prior basis adjustment rules contained in IRC Section 280C(c)(1). The prior statutory language reduced expensing deductions by the amount of the credit, whereas the new language states that costs eligible for amortization are to be reduced by the *excess* of the credit over the deduction. This appears to have generally eliminated the basis adjustment, along with the amortization deduction. A number of economists, accounting firms, and lawyers have argued in support of this interpretation.

Treasury, however, has indicated some uncertainty and presented guidance (Notice 2023-63) for comment on two interpretations of the change, one that retains the original basis adjustment and one that does not. Treasury's case for a basis adjustment rests on the interpretation that the basis adjustment provision refers only to Section 174(a)(1)—referring to expensed amounts, which are zero given the switch to five-year amortization—and not to expenditures that are amortized.

Two points suggest that the basis adjustment has been removed. First, Internal Revenue Code Section 280C(c)(1) states that there should be a basis adjustment if the R&E credit exceeds "the amount allowable as a *deduction* for such taxable year for qualified research expenses or basic research expenses" (emphasis added) and not the amount allowed to be expensed. Section 280C(c)(1) also does not reference the new Section 174 provision that no longer provides for expensing. The provision allowing amortization refers to it as an "amortization *deduction*," which some tax professionals argue is covered under "the amount allowable as a deduction" in 280C(c)(1)(B). This latter point is emphasized in J. Anthony Coughlan, "Be Careful What You Lobby For: R&E Expensing's Heavy Baggage," *Tax Notes Federal*, March 4, 2024. Second, the

TCJA altered Section 280C, which would not be necessary for retaining the basis adjustment.

The Joint Committee on Taxation (JCT) Bluebook (p. 145, footnote 686) seems to be consistent with the excess over the amortization deduction: "Thus, if a taxpayer's research credit under Section 41 for a taxable year beginning after 2021 exceeds the amount allowed as an amortization deduction under the provision for such taxable year, the amount chargeable to capital account under the provision for such taxable year must be reduced by that excess amount."

The legislative history does not address why the basis adjustment was eliminated, and the change has largely gone unnoticed in public debate over restoring expensing. The possibility that it was unintended cannot be ruled out.

The Effect of the Elimination of the Basis Adjustment on Research Subsidies

The effect of switching from expensing with a basis adjustment to five-year amortization without a basis adjustment can be quantified by comparing the benefit for research under both regimes. Prior to 2022, the value of expensing with a basis adjustment for corporate taxpayers was approximately \$0.193 per dollar of investment, computed as 0.21*z*(1-0.082), where z is the present value of expensing (equal to 1) and the basis adjustment is equal to the effective credit estimated by CRS (of 8.2%).

The benefit under five-year amortization with no basis adjustment depends on the nominal discount rate of the firm, which CRS estimates to be 6.39%. At that discount rate, the present value of five-year amortization is \$0.856 for each dollar of investment. Thus, the subsidy under five-year amortization with no basis adjustment is \$0.18 per dollar of investment, computed as 0.21*\$0.856.

With the elimination of the basis adjustment, CRS estimates that the research benefit was reduced by \$0.013 (\$0.193-\$0.18), or 1.3% per dollar of investment due to the switch from expensing with a basis adjustment to five-year amortization without a basis adjustment.

The elimination of the basis adjustment provides a benefit that partially offsets the loss of expensing. CRS estimates that the benefit under five-year amortization with a basis adjustment is \$0.165 per dollar of investment, computed as 0.21*0.856*(1-0.082). Comparing this to the benefit under pre-2022 law (expensing with a basis adjustment) results in a reduction in the subsidy per dollar of investment equal to 2.8% (\$0.193-\$0.165). Thus, the elimination of the basis adjustment offset 54% (1-\$0.013/\$0.028) of the reduction in the benefit that would have occurred had the basis reduction been retained with the switch to five-year amortization. If the discount rate were low enough (around 3.5%), the current amortization regime would be more beneficial than prior law. Amortization also slightly increases the deduction for foreign-derived intangible income.

Budgetary Impact

At the time Congress was considering the TCJA, the JCT estimated that the move to five-year amortization for research would raise \$120 billion within the revenue (FY2018-FY2027) window, largely as part of the transition from expensing, although its permanent gain is much smaller. The JCT estimated that the revenue gain from moving to five-year amortization would reach its peak of \$33 billion in FY2023; by FY2027, it projected the revenue to decrease to \$6 billion, which is approximately in line with the annual gain in "steady state" (i.e., the "long run").

The \$6 billion in annual revenue gain from switching to five-year amortization is reduced by eliminating the basis adjustment. Based on calculations under different assumptions, it appears that the elimination of the basis adjustment was not accounted for in JCT's score of the TCJA. Under that assumption, CRS estimates that elimination of the basis adjustment offsets approximately \$4.3 billion of the \$6 billion in additional annual revenue in steady state. This estimate was made assuming a nominal steady state growth rate of 5%, which implies that amortization as a share of expensing is 88.5% and the effective credit rate is 8.5% (slightly higher than 8.2% because it reflects growth rates rather than discount rates). Combining this with the assumption that the JCT score did not account for elimination of the basis adjustment, it translates into total tax deductions for amortization at that time of \$50.4 billion [\$6 billion*0.885/(0.115*(1-0.085))]. The revenue loss attributable to elimination of the basis reduction is then 0.085*\$50.4 billion, or \$4.3 billion annually.

Although the loss of the basis adjustment offsets 54% of the reduced subsidy and 72% (\$4.3 billion/\$6 billion) of the revenue gain from moving to amortization in the steady state, it had a smaller effect in the TCJA budget horizon. CRS estimates that elimination of the basis offset about 10% (\$12.5 billion/\$120 billion) of the revenue gain from moving to five-year amortization in the TCJA budget horizon. This smaller effect is because in transition to amortization, the amortization deductions are small relative to the gains from expensing initially, and grow over time. For example, in the first year, amortization is 10% of expensing, leading to a larger gain from the difference between expensing and amortization, compared to a smaller effect of the elimination of the basis adjustment on amortization.

Legislative Proposals

Several legislative proposals have been made to restore expensing. S. 866, S. 2823, and H.R. 2673 would permanently return to pre-2022 law. H.R. 7024, the Tax Relief for American Families and Workers Act of 2024, which passed the House, would return to expensing through 2025, when most of the TCJA's temporary provisions expire. All of these proposals would permanently reinstate the basis adjustment that was in effect prior to 2022.

Jane G. Gravelle, Senior Specialist in Economic Policy Mark P. Keightley, Specialist in Economics

Disclaimer

This document was prepared by the Congressional Research Service (CRS). CRS serves as nonpartisan shared staff to congressional committees and Members of Congress. It operates solely at the behest of and under the direction of Congress. Information in a CRS Report should not be relied upon for purposes other than public understanding of information that has been provided by CRS to Members of Congress in connection with CRS's institutional role. CRS Reports, as a work of the United States Government, are not subject to copyright protection in the United States. Any CRS Report may be reproduced and distributed in its entirety without permission from CRS. However, as a CRS Report may include copyrighted images or material from a third party, you may need to obtain the permission of the copyright holder if you wish to copy or otherwise use copyrighted material.